These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The immune landscape of myelodysplastic syndromes. Fozza C; Crobu V; Isoni MA; Dore F Crit Rev Oncol Hematol; 2016 Nov; 107():90-99. PubMed ID: 27823655 [TBL] [Abstract][Full Text] [Related]
4. [Application of cyclosporine A in myelodysplastic syndrome--review]. Guan M Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):678-80. PubMed ID: 14706160 [TBL] [Abstract][Full Text] [Related]
5. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Fozza C; Longinotti M Eur J Haematol; 2012 May; 88(5):380-7. PubMed ID: 22296182 [TBL] [Abstract][Full Text] [Related]
6. [The research update on cellular immune abnormality in myelodysplastic syndrome--review]. Xu F; Liu T Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):673-7. PubMed ID: 14706159 [TBL] [Abstract][Full Text] [Related]
7. Emerging immunosuppressive drugs in myelodysplastic syndromes. Epling-Burnette PK; McDaniel J; Wei S; List AF Expert Opin Emerg Drugs; 2012 Dec; 17(4):519-41. PubMed ID: 23163589 [TBL] [Abstract][Full Text] [Related]
8. Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature. Erden A; Bilgin E; Kılıç L; Sarı A; Armağan B; Büyükaşık Y; Kalyoncu U Drug Metab Pers Ther; 2018 Jun; 33(2):105-108. PubMed ID: 29715182 [TBL] [Abstract][Full Text] [Related]